



PRESS RELEASE

FOR IMMEDIATE RELEASE

Invictus appoints distinguished cancer expert Dr Richard Pestell as Member of Scientific Advisory Board

Melbourne Victoria (22 May 2018) – Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has appointed Dr Richard Pestell as a member of its Scientific Advisory Board.

Dr Pestell (MD, PhD, MBA, FACP, FRACP) is a US-based world-renowned cancer research scientist and physician who has authored over 600 published works (>56,000 citations, H index 128) and 26 book chapters. He is ranked first in the world for prostate cancer and second in the world by Google Scholar Citations for oncology. Dr Pestell has been the Director of two NCI Cancer Centers and was responsible for all oncology clinical trials (Lombardi Cancer Center, Sidney Kimmel Cancer Center from 2002-2015). He was Executive Vice President of Thomas Jefferson University in Philadelphia, prior to his current position as President of the Pennsylvania Cancer and Regenerative Medicine Research Centre. He is an elected Fellow of the American Association for the Advancement of Science, a Fellow of the Royal Society of Medicine, a Fellow of both the American and the Australian College of Physicians and was the founder of two biotechnology companies.

Invictus Biotechnology's Chairman of the Scientific Advisory Board, Dr David Kingston, said:

"Dr Pestell's expertise and networks in the cancer research world will play an integral role in Invictus Biotechnology's development of its drug candidates for pancreatic and other cancers."

"Invictus Biotechnology is taking a novel approach to pancreatic cancer and I am very excited to play a part in the Company's drug development program" added Dr Pestell.



Dr Glenn Tong, Invictus Biotechnology's Executive Chairman, added:

"It is not often that you find in one single individual a person of Richard's stature who has made some spectacular achievements in both science and business through his company Prostagene LLC. Richard is a world-renowned scientist with great entrepreneurial flare and we are absolutely delighted to have him join Invictus Biotechnology's Scientific Advisory Board."

Investor and Media Enquiries:

Dr Douglas Pretsell, Investor and Media Relations
Ph: +61 (0) 409 908 553

Corporate enquiries:

Dr Glenn Tong, Executive Chairman
Ph: +61 (0) 412 193 350

About Invictus Biotechnology

Invictus Biotechnology Pty. Ltd. is a private Australian biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, hyperlipidaemia, hypertension and diabetes. Invictus Biotechnology owns and controls patent and other intellectual property rights for novel approaches to delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

About Dr Richard Pestell MD PhD MBA

Originally from Perth, Australia, Dr Pestell holds a medical degree from the University of Western Australia, and a PhD from the University of Melbourne, Howard Florey Institute. He conducted clinical training in oncology and endocrinology and was inducted as a Fellow of the Royal Australian College of Physicians. His postdoctoral research at the Harvard School of Medicine and Massachusetts General Hospital with Dr Larry Jameson focused on endocrine oncology. He completed his executive MBA from New York University Stern School of Business in 2011. He has received many awards for his research discoveries including elected membership to ASCI (American Society of Clinical Investigation), Elected Member, Royal Society of Medicine, the RD Wright Medallion, Elected Fellow, American Association for the Advancement of Science, the Eric Susman Prize in Medicine, Advance Global Australian Award (Biotechnology), a Doctor of Medical Sciences, *HonorisCausa*, from



the University of Melbourne, and awards from Susan G. Komen (Light of Life award, Jamie Brooke Lieberman Award). He has several issued patents in biotechnology, diagnostics and cancer therapeutics.